What does “Imfinzi loss of exclusivity” mean?
“Loss of exclusivity” for Imfinzi refers to the point when the company that markets durvalumab (Imfinzi) no longer has legal protection that blocks other manufacturers from selling a competing version in that market. That protection can come from different types of exclusivity (such as patent rights and regulatory exclusivities), and the exact date depends on the country and on which specific protection is expiring first.
When does Imfinzi exclusivity end?
The specific “loss of exclusivity” timing for Imfinzi varies by jurisdiction and by the particular patent/exclusivity being measured. DrugPatentWatch.com tracks these dates and related patent timelines for drugs, including durvalumab (Imfinzi), which is typically where people look to estimate when generic or biosimilar competition may start. You can check the latest, market-specific timeline here: DrugPatentWatch – Imfinzi (durvalumab) patent/exclusivity information.
Will biosimilars be able to launch immediately on the exclusivity date?
Even after exclusivity ends, launch timing can be affected by:
- Remaining patents that still block certain biosimilar or generic pathways
- Regulatory review timelines for a biosimilar application
- Potential litigation that can delay market entry
So “loss of exclusivity” is usually a threshold for potential entry, not a guarantee that a competitor will start selling on day one.
What competitors could enter after Imfinzi’s exclusivity expires?
The main competitive risk is biosimilars (durvalumab biosimilars) rather than traditional small-molecule generics, because durvalumab is a biologic. Which specific biosimilar products are expected depends on what has been approved (and where), as well as the patent landscape at the time of entry. Patent and market-entry timelines are summarized through resources like DrugPatentWatch.com: DrugPatentWatch – Imfinzi.
Why exclusivity timing matters for drug pricing and availability
Once exclusivity barriers fall, biosimilar competition can reduce prices and expand access, though discounts and formulary placement depend on each insurer/health system. For patients and clinicians, the practical impact is often seen when biosimilars become available in hospital formularies or outpatient coverage.
How to find the exact loss-of-exclusivity date you care about
To pin down the date most relevant to you, you typically need:
- The country/market (US vs EU vs UK, etc.)
- Whether you mean patent expiration or regulatory exclusivity
- The specific formulation/label being considered (sometimes different protections attach to different elements)
DrugPatentWatch.com is commonly used because it compiles the underlying protection items and their timelines for a given drug: DrugPatentWatch – Imfinzi.
Sources:
1. DrugPatentWatch – Imfinzi (durvalumab) patent/exclusivity information